1. Home
  2. EDF vs KRRO Comparison

EDF vs KRRO Comparison

Compare EDF & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

EDF

Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

HOLD

Current Price

$5.14

Market Cap

166.0M

Sector

Finance

ML Signal

HOLD

Logo Korro Bio Inc.

KRRO

Korro Bio Inc.

HOLD

Current Price

$11.06

Market Cap

187.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDF
KRRO
Founded
N/A
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.0M
187.9M
IPO Year
2010
2019

Fundamental Metrics

Financial Performance
Metric
EDF
KRRO
Price
$5.14
$11.06
Analyst Decision
Buy
Analyst Count
0
12
Target Price
N/A
$34.80
AVG Volume (30 Days)
146.3K
224.0K
Earning Date
01-01-0001
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$6,392,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
181.46
52 Week Low
$4.72
$5.20
52 Week High
$5.67
$55.89

Technical Indicators

Market Signals
Indicator
EDF
KRRO
Relative Strength Index (RSI) 34.14 37.08
Support Level $4.81 $10.81
Resistance Level $5.19 $14.53
Average True Range (ATR) 0.10 0.97
MACD -0.04 -0.33
Stochastic Oscillator 6.19 1.77

Price Performance

Historical Comparison
EDF
KRRO

About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest

Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.

About KRRO Korro Bio Inc.

Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability. The company operates and manages its business as one reportable segment and one operating segment, which is the business of discovering, developing and commercializing therapies derived from or incorporating its RNA-editing technology.

Share on Social Networks: